Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent CXCR4 antagonist and an anti-angiogenic drug that is of potential value in treating choroid neovascularization.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | Inquiry | |
50 mg | 6-8 weeks | Inquiry | |
100 mg | 6-8 weeks | Inquiry |
Description | Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent CXCR4 antagonist and an anti-angiogenic drug that is of potential value in treating choroid neovascularization. |
In vitro | Burixafor hydrobromide mobilizes mesenchymal stem cells, attenuates inflammation, and preserves cardiac systolic function in a porcine model of myocardial infarction [2]. |
Synonyms | TG-0054 hydrobromide |
Molecular Weight | 647.644 |
Formula | C27H52BrN8O3P |
CAS No. | 1191450-19-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 50 mg/mL (65.02 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Burixafor hydrobromide 1191450-19-7 Autophagy GPCR/G Protein Immunology/Inflammation CXCR TG 0054 Hydrobromide TG-0054 Hydrobromide TG0054 Hydrobromide Burixafor Hydrobromide TG-0054 hydrobromide inhibitor inhibit